Rafa Laboratories Overview
Rafa Laboratories is a pharmaceutical company that markets, manufactures, and distributes consumer health products and prescription and over-the-counter medicines, mainly proprietary formulations as well as generic formulations. The company manufactures a wide variety of medications based on in-house development and through external agreements. Rafa Laboratories is also involved in marketing drugs produced by international corporations such as Dr. Falk Pharma, Helsinn Healthcare, Boehringer Ingelheim, Purdue Pharma, 3M Healthcare, United Therapeutics, and Mundipharma. Rafa Laboratories received FDA approval for their 10 mg midazolam autoinjector, which can treat seizures caused by nerve agent exposure.
Latest News
growth-positive
שווי של 1.2 מיליארד שקל: פימי במגעים למכירת 10%–15% מרפא
Almost four years after acquiring a controlling stake (88%) in the pharmaceutical company Rafa Laboratories, the private equity fund FIMI is in preliminary talks to sell a 10%-15% stake to institutional investors. The accelerated growth in the field of automatic syringes for treating seizures due to exposure to biological weapons and the distribution of rare drugs in Europe allows FIMI to demand a high amount. The valuation for this sale is expected to be double the amount FIMI paid when it acquired control of Rafa at the end of 2020.
Investment
growth-positive
Rafa Receives FDA Approval For Life-saving Midazolam Autoinjector
Rafa Laboratories LTD has received FDA approval for its first in market 10 mg midazolam autoinjector for the treatment of status epilepticus in adults. The product was developed in partnership with the U.S. Department of Defenses (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). The autoinjector can be used to treat seizures resulting from nerve agent exposure and will replace the currently fielded convulsant antidote for nerve agent (CANA) diazepam autoinjector. The product was developed in Israel and is already sold under EUA in other territories.
PartnersCustomers
growth-positive
Rafa Laboratories to acquire a significant stake in ExCEEd Orphan and expand its international capabilities in medicines addressing rare diseases
Rafa Laboratories has announced a strategic collaboration with ExCEEd Orphan for medicines addressing rare diseases in Central and Eastern Europe (CEE) and Israel. Rafa will invest an undisclosed amount in ExCEEd to strengthen its market access capabilities in the region. The collaboration aims to bring new medicines for rare diseases to both CEE and Israel. The worldwide orphan drug market is growing rapidly, and Rafas investment in ExCEEd demonstrates its commitment to becoming a leading player in this field. ExCEEd has already signed agreements with leading pharma companies, and the collaboration with Rafa will further facilitate access to medicines for rare diseases in CEE countries.
PartnersInvestmentExpand
growth-negative
FIMI buys Rafa from Sackler family at NIS 700m valuation
The Sackler family has sold its controlling stake in Rafa Laboratories Ltd. due to the fallout from the opioid scandal. FIMI Opportunity Funds has acquired a 90% stake in Rafa Laboratories at a company valuation of NIS 700 million. Rafa Laboratories is an Israeli pharmaceutical company that manufactures generic pharmaceuticals for marketing in Israel. The company has hundreds of employees and a factory in Jerusalem. The entry of FIMI as the senior partner will allow the continued operations of the factory and the promotion of Rafas business in Israeli and overseas markets.
Acquisition
growth-negative
Sackler family in talks to sell control of Rafa to FIMI
The Sackler family is selling its 78% stake in Rafa Laboratories Ltd. due to its involvement in the opioid affair in the US. FIMI Opportunity Funds is in talks to acquire Rafa at a company valuation of NIS 700 million. The Sackler family owns Purdue Pharma, which filed for bankruptcy protection after the opioid scandal. Rafa is an Israeli pharmaceutical company that manufactures generic pharmaceuticals for the Israeli market. This acquisition would be one of FIMIs largest in recent years and expands its healthcare portfolio.
Acquisition
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Acquired |
| Rounds | 0 |
| Investors | 0 |
Team Members
4
Employees: 51-200
Web & Social Links
| Website | www.rafa.co.il/en |
| Careers | Careers page |
Locations
Shlomo Momo ha-Levi St 5, Jerusalem, Israel
Photos & Videos
No files yet
